SCHEMBL5026147

SCHEMBL5026147

CCOC(=O)c1sc2nc(-c3cccs3)nc(-c3cccc(N)c3)c2c1N

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 8/20 0.52
ALDH1A1 P00352 8/20 0.52
MAPT P10636 8/20 0.52
GAA P10253 3/20 0.52
L3MBTL1 Q9Y468 2/20 0.52
MAPK1 P28482 1/20 0.52
HPGD P15428 10/20 0.49
SMN1; SMN2 Q16637 4/20 0.48
HSD17B10 Q99714 2/20 0.48
GLA P06280 1/20 0.48
CASP1 P29466 1/20 0.48
CASP7 P55210 1/20 0.48
ATM Q13315 1/20 0.48
KMT2A Q03164 5/20 0.46
NPSR1 Q6W5P4 2/20 0.46
HIF1A Q16665 1/20 0.46
NPC1 O15118 2/20 0.45
RAB9A P51151 2/20 0.45
IKBKB O14920 1/20 0.45
BRAF P15056 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6218118 0.91 LHCGR (0.53) KDM4EALDH1A1MAPTGAAL3MBTL1
SCHEMBL6217700 0.91 HPGD (0.59) KDM4EALDH1A1MAPTGAAL3MBTL1
SCHEMBL5024695 0.88 MAPT (0.54) KDM4EALDH1A1MAPTGAAL3MBTL1
SCHEMBL4418734 0.88 KDM4E (0.62) KDM4EALDH1A1MAPTGAAL3MBTL1
SCHEMBL5026177 0.87 KDM4E (0.54) KDM4EALDH1A1MAPTGAAL3MBTL1
SCHEMBL6216251 0.86 KDM4E (0.49) KDM4EALDH1A1MAPTGAAL3MBTL1
SCHEMBL5026164 0.86 HPGD (0.50) KDM4EALDH1A1MAPTL3MBTL1MAPK1
SCHEMBL5026126 0.86 BRAF (0.59) KDM4EALDH1A1MAPTMAPK1HPGD
SCHEMBL6218049 0.85 KDM4E (0.48) KDM4EALDH1A1MAPTGAAL3MBTL1
SCHEMBL5026123 0.83 KDM4E (0.54) KDM4EALDH1A1MAPTGAAL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7375109-B2 Glycine-substituted thieno[2,3-d]pyrimidines with combined LH and FSH agonistic activity N.V. ORGANON (NL) 2008-05-20 US disclosed
EP-1427734-B1 GLYCINE-SUBSTITUTED THIENO[2,3-d]PYRIMIDINES WITH COMBINED LH AND FSH AGONISTIC ACTIVITY AKZO NOBEL NV (NL) 2005-11-09 EP disclosed
US-20040180907-A1 Glycine-substituted thieno{2,3-d}pyrimidines with combined lh and fsh agonistic activity MERCK SHARP & DOHME B.V. (NL) 2004-09-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040180907-A1 Glycine-substituted thieno{2,3-d}pyrimidines with combined lh and fsh agonistic activity FSHR, GNRHR, LHCGR KDM4E 1976/4885ALDH1A1 1676/4885MAPT 4881/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.